NASDAQ$ALXO
ALX Oncology Holdings Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results and provided clinical development and operational highlights.
ALX Oncology reported a GAAP net loss of $30.2 million for the first quarter ended March 31, 2023, compared to a GAAP net loss of $24.5 million for the first quarter ended March 31, 2022. The company's cash, cash equivalents, and investments totaled $256.2 million as of March 31, 2023.
- Advanced lead program, evorpacept, through new collaborations and clinical trial starts.
- Announced clinical trial collaboration with Sanofi to evaluate evorpacept in combination with SARCLISA in patients with multiple myeloma.
- Initiated three new clinical studies, including a Phase 1 trial in urothelial cancer in combination with PADCEV.
- First patient dosed in Phase 2 investigator-sponsored trial of evorpacept in combination with KEYTRUDA in patients with ovarian cancer.
Headline financials
Revenue & EPS history
ALX Oncology · Revenue · Quarterly
$0
Forward guidance
ALX Oncology believes its cash, cash equivalents, investments along with the ability to draw down an additional $40 million of its term loan are sufficient to fund planned operations through mid-2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.7%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+26.0%
Q4 2024
Best reaction
-21.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -10.2% | -6.8% | -13.2% | |
| Q3 2025 | +15.5% | +8.5% | +20.3% | |
| Q2 2025 | +7.4% | +57.9% | +72.4% | |
| Q1 2025 | -8.2% | -0.2% | +25.9% | |
| Q4 2024 | +26.0% | -6.4% | -50.4% | |
| Q3 2024 | -5.2% | -12.4% | +5.9% | |
| Q1 2024 | -2.4% | -8.7% | -45.8% | |
| Q4 2023 | +3.0% | -16.2% | -17.2% | |
| Q3 2023 | +13.2% | +21.8% | +70.5% | |
| Q2 2023 | +1.4% | -2.6% | -1.4% | |
| Q1 2023 | +0.6% | -7.0% | +23.3% | |
| Q4 2022 | -13.6% | -15.9% | -28.7% | |
| Q3 2022 | -1.8% | +1.1% | -14.2% | |
| Q2 2022 | +2.6% | +26.6% | +5.6% | |
| Q1 2022 | -6.8% | -8.1% | -24.1% | |
| Q4 2021 | +7.7% | -1.3% | +2.7% | |
| Q3 2021 | +8.8% | +6.3% | -26.4% | |
| Q2 2021 | +0.6% | +2.1% | +16.6% | |
| Q1 2021 | -1.1% | -1.6% | +7.3% | |
| Q4 2020 | -21.9% | -19.4% | -24.8% | |
| Q3 2020 | +4.2% | +34.6% | +65.1% | |
| Q2 2020 | +2.0% | -3.8% | -10.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro